|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer显示文摘 | Hongyan Huang Zefei Jiang Tao Wang Shaohua Zhang Li Bian Yang Cao Shikai Wu Santai Song | 2012 | Anti-Cancer Drugs2012，，7： | 1 |
| 2 | Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy显示文摘 | Shikai Wu Yang Zhang Liyan Xu Yun Dai Yuee Teng Shanshan Ma Seong-Hyun Ho Jong-Mook Kim Seung Yu Sunyoung Kim Santai Song | 2012 | Supportive Care in Cancer2012，，8： | 1 |
| 3 | Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer显示文摘 | Tao Wang Shaohua Zhang Min Zeng Xinyou Lu Ge Shen Shikai Wu Santai Song Zefei Jiang | 2012 | Medical Oncology2012，，1： | 1 |
| 4 | 实时荧光PCR法检测肺癌细胞系中吉西他滨耐药相关基因的表达(英文)显示文摘Objective: To explore the molecular mechanism of gemcitabine-resistance, the relative mRNA expression of five genes related to gemcitabine-resistance was detected in six lung cancer cell lines. Methods: The total RNA was extracted from six lung cancer cell lines GLC-82, NCI-H460, A549, 95-C, 95-D and QG56. Then the cDNA was amplified by real-time quantitative PCR method to quantify the gene expression of RRM1, PTEN, ERCC1, dCK and CDA. The cytotoxicity of gem- citabine to cell lines was tested by MTT method. Results: Among the detected six lung cancer cell lines, the mRNA level of RRM1, PTEN and ERCC1 in lung squamous cell line QG56 was highest, and the IC50 of gemcitabine to QG56 cell line was also highest. Conclusion: The mRNA expression of RRM1, PTEN and ERCC1 was correlated, and the high expression of RRM1 was related to gemcitabine resistance of lung cancer. | Li Lin Xiaoqing Liu Yalan Rao Weixia Wang Shengqi Wang Santai Song | 2008 | The Chinese-German Journal of Clinical Oncology2008，7，12： | 0 |
| 5 | 原癌基因Fra-1在乳腺恶性肿瘤组织中的表达(英文)显示文摘Objective:Invasion and metastasis are the most significant and intrinsic biological characteristics of cancers,also which are main factors of malignant tumor causing treatment failure and death.Recent studies have found that Fra-1 plays an important role on cell migration,invasion,and maintaining malignant phenotype of transformed cells.But there are few studies about the expression and location of Fra-1 in breast tissues and cells being reported.This study just aims to discuss the expression and location of transcription factor Fra-1 in benign and malignant human breast tissues.Methods:The expression of Fra-1 was investigated by immunohistochemistry in neoplastic breast diseases ranging from benign fibroadenoma to very aggressive undifferentiated carcinoma.The correlations of Fra-1 expression with other indicators of breast carcinoma prognosis (ER,PR and ErbB2 receptors) were analyzed.Results:All neoplastic breast tissues,either benign or malignant breast tissues,were nuclear immunoreactive for Fra-1-recognizing antibody.In 85% of benign tumors (17/20),the immunoreactive for Fra-1-recognizing antibody as exclusively restricted to the nuclei.In three cases (3/20,15%),focal unequivocal cytoplasmic staining was also exhibited.Strong positive nuclear staining for Fra-1 was easily seen in all types of breast carcinomas.However the nuclear/cytoplasmic concomitant immunoreactivity was observed in all types of breast carcinomas.A clear shift in Fra-1 immunoreactivity,from an exclusively nuclear to a simultaneous nuclear and cytoplasmic localization was noticed in 90.2% (37/41) of breast carcinomas.No inverse relationship between Fra-1 and ER and PR protein levels was noticed in malignant tumors.The relative expression level of Fra-1 was not correlated with the expression of ErbB2.Conclusion:The overall expression,pattern and intensity of Fra-1 proteins were correlated with breast oncogenesis.Overexpression of Fra-1,leading to a persistent high cytoplasmic accumulation,may play a role in the process of breast carcinogenesis. | Yuhua Song Jing Wang Xiaoyun Yu Santai Song Zefei Jiang | 2012 | The Chinese-German Journal of Clinical Oncology2012，11，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员